menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Special Report: What Went Wrong With ACCORD?

close
Special Report: What Went Wrong With ACCORD?
Restart
Resume
Choose a format
Media formats available:
Details
Presenters
Comments
  • Overview

    What went wrong with the glucose-lowering arm of the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Trials? Intensive therapy was expected to reduce cardiovascular events in Type 2 diabetics at high risk of cardiovascular disease. Instead, it appears to have led to an increase in mortality. Dr. John Buse, president of the American Diabetes Association and vice chair of the ACCORD Trials Steering Committee, details the confounding results of ACCORD and offers a few ideas to explain the unexpected outcomes. Dr. Matthew Sorrentino hosts.

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    What went wrong with the glucose-lowering arm of the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Trials? Intensive therapy was expected to reduce cardiovascular events in Type 2 diabetics at high risk of cardiovascular disease. Instead, it appears to have led to an increase in mortality. Dr. John Buse, president of the American Diabetes Association and vice chair of the ACCORD Trials Steering Committee, details the confounding results of ACCORD and offers a few ideas to explain the unexpected outcomes. Dr. Matthew Sorrentino hosts.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 5/30/20